Objective To study the clinical and prognostic significance of the preferentially expressed antigen of melanoma (PRAME) gene in the absence of specific fusion gene expression in children with B-lineage acute lymphoblastic leukemia (B-ALL). Methods A total of 167 children newly diagnosed with B-ALL were enrolled, among whom 70 were positive for the PRAME gene and 97 were negative. None of the children were positive for MLL-r, BCR/ABL, E2A/PBX1, or ETV6/RUNX1. The PRAME positive and negative groups were analyzed in terms of clinical features, prognosis, and related prognostic factors. Results Compared with the PRAME negative group, the PRAME positive group had a significantly higher proportion of children with the liver extending >6 cm below the costal margin (P<0.05). There was a significant reduction in the PRAME copy number after induction chemotherapy (P<0.05). In the minimal residual disease (MRD) positive group after induction chemotherapy, the PRAME copy number was not correlated with the MRD level (P>0.05). In the MRD negative group, there was also no correlation between them (P>0.05). The PRAME positive group had a significantly higher 4-year event-free survival rate than the PRAME negative group (87.5%±4.6% vs 73.5%±4.6%, P<0.05), while there was no significant difference between the two groups in the 4-year overall survival rate (88.0%±4.4% vs 85.3%±3.8%, P>0.05). The Cox proportional-hazards regression model analysis showed that positive PRAME expression was a protective factor for event-free survival rate in children with B-ALL (P<0.05). Conclusions Although the PRAME gene cannot be monitored as MRD, overexpression of PRAME suggests a good prognosis in B-ALL. Citation:Chinese Journal of Contemporary Pediatrics, 2022, 24(5): 543-549
Key words
Acute lymphoblastic leukemia /
Preferentially expressed antigen of melanoma /
Minimal residual disease /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia[J]. Haematologica, 2020, 105(11): 2524-2539. PMID: 33054110. PMCID: PMC7604619. DOI: 10.3324/haematol.2020.247031.
2 Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia[J]. J Clin Oncol, 2017, 35(9): 975-983. PMID: 28297628. PMCID: PMC5455679. DOI: 10.1200/JCO.2016.70.7836.
3 Schwab C, Harrison CJ. Advances in B-cell precursor acute lymphoblastic leukemia genomics[J]. Hemasphere, 2018, 2(4): e53. PMID: 31723781. PMCID: PMC6746003. DOI: 10.1097/HS9.0000000000000053.
4 Khateeb EE, Morgan D. Preferentially expressed antigen of melanoma (PRAME) and Wilms' tumor 1 (WT 1) genes expression in childhood acute lymphoblastic leukemia, prognostic role and correlation with survival[J]. Open Access Maced J Med Sci, 2015, 3(1): 57-62. PMID: 27275197. PMCID: PMC4877789. DOI: 10.3889/oamjms.2015.001.
5 Paydas S, Tanriverdi K, Yavuz S, et al. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects[J]. Am J Hematol, 2005, 79(4): 257-261. PMID: 16044453. DOI: 10.1002/ajh.20425.
6 Ikeda H, Lethé B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor[J]. Immunity, 1997, 6(2): 199-208. PMID: 9047241. DOI: 10.1016/s1074-7613(00)80426-4.
7 Zhang YH, Lu AD, Yang L, et al. PRAME overexpression predicted good outcome in pediatric B-cell acute lymphoblastic leukemia patients receiving chemotherapy[J]. Leuk Res, 2017, 52: 43-49. PMID: 27875783. DOI: 10.1016/j.leukres.2016.11.005.
8 Abdelmalak CA, Yahya RS, Elghannam DM, et al. PRAME gene expression in childhood acute lymphoblastic leukemia: impact on prognosis[J]. Clin Lab, 2014, 60(1): 55-61. PMID: 24600975. DOI: 10.7754/clin.lab.2013.121137.
9 Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-2405. PMID: 27069254. DOI: 10.1182/blood-2016-03-643544.
10 Qin Y, Zhu H, Jiang B, et al. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease[J]. Leuk Res, 2009, 33(3): 384-390. PMID: 18950857. DOI: 10.1016/j.leukres.2008.08.026.
11 Xue YJ, Cheng YF, Lu AD, et al. Allogeneic hematopoietic stem cell transplantation, especially haploidentical, may improve long-term survival for high-risk pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era[J]. Biol Blood Marrow Transplant, 2019, 25(8): 1611-1620. PMID: 30537550. DOI: 10.1016/j.bbmt.2018.12.007.
12 Wang Y, Zeng HM, Zhang LP. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol[J]. Ital J Pediatr, 2018, 44(1): 94. PMID: 30115129. PMCID: PMC6097322. DOI: 10.1186/s13052-018-0541-6.
13 Steinbach D, Hermann J, Viehmann S, et al. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia[J]. Cancer Genet Cytogenet, 2002, 133(2): 118-123. PMID: 11943337. DOI: 10.1016/S0165-4608(01)00570-2.
14 Spanaki A, Perdikogianni C, Linardakis E, et al. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia[J]. Leuk Res, 2007, 31(5): 639-642. PMID: 16860864. DOI: 10.1016/j.leukres.2006.06.006.
15 Matsushita M, Ikeda H, Kizaki M, et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia[J]. Br J Haematol, 2001, 112(4): 916-926. PMID: 11298586. DOI: 10.1046/j.1365-2141.2001.02670.x.
16 Ding K, Wang XM, Fu R, et al. PRAME gene expression in acute leukemia and its clinical significance[J]. Cancer Biol Med, 2012, 9(1): 73-76. PMID: 23691459. PMCID: PMC3643640. DOI: 10.3969/j.issn.2095-3941.2012.01.013.
17 Tanaka N, Wang YH, Shiseki M, et al. Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells[J]. Leuk Res, 2011, 35(9): 1219-1225. PMID: 21550659. DOI: 10.1016/j.leukres.2011.04.005.
18 Carroll AJ, Shago M, Mikhail FM, et al. Masked hypodiploidy: hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: a report from the Children's Oncology Group[J]. Cancer Genet, 2019, 238: 62-68. PMID: 31425927. PMCID: PMC6768693. DOI: 10.1016/j.cancergen.2019.07.009.
19 Huang Z, Jia Y, Ruan G, et al. Quantitative analysis of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia: higher levels are associated with a poorer prognosis[J]. Pediatr Hematol Oncol, 2021, 28: 1-11. PMID: 34582325. DOI: 10.1080/08880018.2021.1966558.
PDF(559 KB)
